COPD. other chronic obstructive pulmonary disease
Conditions
Interventions
Intervention 1: Intervention group: In this group?60 capsules of rosemary extract with a dose of 500 mg twice at 7 to 9 in the morning and maintaining a distance of 12 hours?again at 19 to 21 at night
Sponsors
Khoram-Abad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age between 40 and 80 years The ratio of FEV1 to FVC is less than 0.7 exhalation pressure volume per second (FEV1)?less than 70% of reference value and increase in FEV1 less than 10% after inhalation of beta-two agonists Detection of COPD based on grade one to three gold criteria approved by spirometry and physician Patients with mild to moderate cognitive impairment based on MMSE test with a minimum score of 23 Have a history of smoking at least ten packs of cigarettes a year At least one year has passed since the diagnosis of COPD in the patient Do not take any herbal medicine supplements effective in improving cognitive function and lung function and daily activity (such as Ginseng?Thyme?Nigella sativa?Chamomile?etc)from two months ago No alcohol?hookah and drugs Do not take antioxidants as a supplement during the last three months(vitamin E?Omega3?a-tocopherol?etc)
Exclusion criteria
Exclusion criteria: Lack of motivation of the patient to continue cooperation Hospitalization during the study Neurological disease?cancer?acute infection and known mental disorders(anxiety?depression and delirium) Patient deterioration?unstable hemodynamic status?life threatening arrhythmias Participate in other pulmonary rehabilitation programs or meditation and yoga Do not take the capsules for two consecutive days Demonstrate sensitivity to capsules If the patient needs to take drugs that affect cognitive or pulmonary function or the amount of daily activity (such as muscle relaxants?etc)during the study?in addition to the main treatment drugs?excluded from the study Patients receiving vasodilators include organic nitrates and people with pulmonary ?hypertension?obstructive sleep apnea?malignancies?gastrointestinal abnormalities?recent surgery?severe endocrine disease?kidney disease?liver disease?inflammatory and infectious disease?and musculoskeletal disease active that causes impairment in exercise and respiratory capacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Montreal Cognitive Dysfunction Questionnaire.;Pulmonary function. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Spirometry device.;Activity daily of living. Timepoint: Before starting treatment and one week after completing the 60 day treatment period. Method of measurement: Lawton and London Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArash momeni safarabadi
Khoram-Abad University of Medical Sciences
Outcome results
None listed